Allergan (AGN) Offering Possible 23.76% Return Over the Next 6 Calendar Days

This article was originally published on this site

Allergan’s most recent trend suggests a bullish bias. One trading opportunity on Allergan is a Bull Put Spread using a strike $162.50 short put and a strike $157.50 long put offers a potential 23.76% return on risk over the next 6 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $162.50 by expiration. The full premium credit of $0.96 would be kept by the premium seller. The risk of $4.04 would be incurred if the stock dropped below the $157.50 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Allergan is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Allergan is bullish.

The RSI indicator is at 55.85 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Allergan

American Medical Association Rejects Idea of Time Limits on Opioid Scripts
Wed, 11 Apr 2018 19:45:00 +0000
While more than half the states in the U.S. have passed time limits on opioid prescription as a way to battle the epidemic, the AMA says that should be left up to the doctor and patient.

FDA Prolongs Review Date for AbbVie Endometriosis Candidate
Wed, 11 Apr 2018 15:36:03 +0000
The FDA extends the review period of NDA for AbbVie (ABBV) and partner Neurocrine Biosciences’ endometriosis candidate, elagolix, by three months to third-quarter 2018.

Allergan Stock Performance in 1Q18
Tue, 10 Apr 2018 19:03:21 +0000
Allergan (AGN) is one of the leading pharmaceutical companies. It deals with both generic and specialty pharmaceutical products. Its headquarters are in Dublin, Ireland. Its US administrative headquarters are in Parsippany, New Jersey. Allergan has segregated its business into three segments: US General Medicine, US Specialized Therapeutics, and International.

Edited Transcript of AGN presentation 8-Mar-17 1:40pm GMT
Tue, 10 Apr 2018 15:00:17 +0000
Allergan plc at Raymond James Institutional Investors Conference

Analyst Recommendations for Teva Pharmaceutical in April 2018
Tue, 10 Apr 2018 14:31:25 +0000
In December 2017, the FDA accepted Teva Pharmaceutical Industries’ (TEVA) BLA (Biologics License Application) for fremanezumab for the preventive treatment of migraine. In February 2018, the European Medicines Agency accepted the MAA (Marketing Authorization Application) for fremanezumab for the treatment of adults with episodic and chronic migraine. In January 2018, the FDA approved Teva Pharmaceutical’s Trisenox and tretinoin combination therapy for the treatment of individuals with newly-diagnosed, low-risk APL (acute promyelocytic leukemia) with a presence of PML/RAR alpha gene expression.

Be Sociable, Share!

Related Posts